The Food and Drug Administration Friday issued warning letters to all three duodenoscope manufacturers for failing to comply with a 2015 order to conduct postmarket surveillance studies to determine whether health care facilities are able to properly clean and disinfect the devices. “The FDA has taken important steps to improve the reprocessing of duodenoscopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly implemented in real-world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “We expect these device manufacturers to meet their study obligations to ensure patient safety.” The letters were sent to Olympus, Fujifilm and Pentax, who are expected to submit a plan by March 24 outlining how study milestones will be achieved.

Related News Articles

Headline
The Food and Drug Administration has identified Class I recalls for the following products due to the potential for serious injury or death:Certain lots of…
Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares insights into the organization’s bold approach to improving safety outcomes. From piloting…
Headline
The AHA Quest for Quality Prize honors hospitals and health systems committed to leadership and innovation in improving quality and advancing health. Learn how…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Blog
Read about the 2025 Quest for Quality Prize winner and finalist — and apply for the 2026 awardEach day, health care professionals across the U.S. leverage…
Headline
A study published by JAMA Aug. 13 found that a two-dose antibiotic treatment could be just as effective as traditional long-term IV therapy for treating…